Optimization of the Process for Preparing Bivalent Polysaccharide Conjugates to Develop Multivalent Conjugate Vaccines against Streptococcus pneumoniae or Neisseria meningitidis and Comparison with the Corresponding Licensed Vaccines in Animal Models

Abstract

Objective

This study aimed to describe, optimize and evaluate a method for preparing multivalent conjugate vaccines by simultaneous conjugation of two different bacterial capsular polysaccharides (CPs) with tetanus toxoid (TT) as bivalent conjugates.

Methods

Different molecular weights (MWs) of polysaccharides, activating agents and capsular polysaccharide/protein (CP/Pro) ratio that may influence conjugation and immunogenicity were investigated and optimized to prepare the bivalent conjugate bulk. Using the described method and optimized parameters, a 20-valent pneumococcal conjugate vaccine and a bivalent meningococcal vaccine were developed and their effectiveness was compared to that of corresponding licensed vaccines in rabbit or mouse models.

Results

The immunogenicity test revealed that polysaccharides with lower MWs were better for Pn1-TT-Pn3 and MenA-TT-MenC, while higher MWs were superior for Pn4-TT-Pn14, Pn6A-TT-Pn6B, Pn7F-TT-Pn23F and Pn8-TT-Pn11A. For activating polysaccharides, 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) was superior to cyanogen bromide (CNBr), but for Pn1, Pn3 and MenC, N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDAC) was the most suitable option. For Pn6A-TT-Pn6B and Pn8-TT-Pn11A, rabbits immunized with bivalent conjugates with lower CP/Pro ratios showed significantly stronger CP-specific antibody responses, while for Pn4-TT-Pn14, higher CP/Pro ratio was better. Instead of interfering with the respective immunological activity, our bivalent conjugates usually induced higher IgG titers than their monovalent counterparts.

Conclusion

The result indicated that the described conjugation technique was feasible and efficacious to prepare glycoconjugate vaccines, laying a solid foundation for developing extended-valent multivalent or combined conjugate vaccines without potentially decreased immune function.

References

[1] PaceD. Glycoconjugate vaccines. Expert Opin Biol Ther, 2013, 13(1): 11-33

[2] PrincipiN, EspositoS. Development of pneumococcal vaccines over the last 10 years. Expert Opin Biol Ther, 2018, 18(1): 7-17

[3] MasomianM, AhmadZ, GewLT, et al.. Development of Next Generation Streptococcus pneumoniae Vaccines Conferring Broad Protection. Vaccines, 2020, 8(1): 132

[4] OligbuG. Higher Valent Pneumococcal Conjugate Vaccines: is it a roller coaster?. AIMS Public Health, 2020, 7(1): 29-32

[5] PeltonSI. The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines. J Adolesc Health, 2016, 59(2): S3-S11 Supplement

[6] AdamoR, NiloA, HarfoucheC, et al.. Investigating the immunodominance of carbohydrate antigens in a bivalent unimolecular glycoconjugate vaccine against serogroup A and C meningococcal disease. Glycoconjugate J, 2014, 31(9): 637-647

[7] MéndezY, ChangJ, HumpierreAR, et al.. Multicomponent polysaccharide—protein bioconjugation in the development of antibacterial glycoconjugate vaccine candidates. Chem Sci, 2018, 9(9): 2581-2588

[8] HumpierreAR, ZanuyA, SaenzM, et al.. Expanding the Scope of Ugi Multicomponent Bioconjugation to Produce Pneumococcal Multivalent Glycoconjugates as Vaccine Candidates. Bioconjugate Chem, 2020, 31(9): 2231-2240

[9] LeesA, NelsonBL, MondJJ. Activation of soluble polysaccharides with 1-cyano-4-dimethy-laminopyridinium tetrafluoroborate for use in protein—polysaccharide conjugate vaccines and immunological reagents. Vaccine, 1996, 14(3): 190-198

[10] ChuC, SchneersonR, RobbinsJB, et al.. Further Studies on the Immunogenicity of Haemophilus influenzae Type b and Pneumococcal Type 6A Polysaccharide-Protein Conjugates. Infect Immun, 1983, 40(1): 245-256

[11] BertiF, RomanoMR, MicoliF, et al.. Relative stability of meningococcal serogroup A and X polysaccharides. Vaccine, 2012, 30(45): 6409-6415

[12] ThompsonA, LamberthE, SeversJ, et al.. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. Vaccine, 2019, 37(42): 6201-6207

[13] ScottDA, KomjathySF, HuBT, et al.. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. Vaccine, 2007, 25(33): 6164-6166

[14] BertiF, MicoliF. Improving efficacy of glycoconjugate vaccines: from chemical conjugates to next generation constructs. Curr Opin Immunol, 2020, 65: 42-49

[15] BrökerM, BertiF, CostantinoP. Factors contributing to the immunogenicity of meningococcal conjugate vaccines. Hum Vacc Immunother, 2016, 12(7): 1808-1824

[16] Biemans R, Micoli F, Romano MR. 8-Glycoconjugate vaccines, production and characterization. In: Rauter AP, BE Christensen, L Somsák, et al., eds. Recent Trends in Carbohydrate Chemistry: Elsevier, 2020:285–313

[17] AvciF, BertiF, DullP, et al.. Glycoconjugates: What It Would Take To Master These Well-Known yet Little-Understood Immunogens for Vaccine Development. mSphere, 2019, 4(5): e00520-00519

[18] MicoliF, Del BinoL, AlfiniR, et al.. Glycoconjugate vaccines: current approaches towards faster vaccine design. Expert Rev Vaccines, 2019, 18(9): 881-895

[19] RanaR, DalalJ, SinghD, et al.. Development and characterization of Haemophilus influenzae type b conjugate vaccine prepared using different polysacc-haride chain lengths. Vaccine, 2015, 33(23): 2646-2654

[20] LockyerK, GaoF, FrancisRJ, et al.. Higher mass meningococcal group C-tetanus toxoid vaccines conjugated with carbodiimide correlate with greater immunogenicity. Vaccine, 2020, 38(13): 2859-2869

[21] LaferriereCA, SoodRK, De MuysJM, et al.. Streptococcus pneumoniae Type 14 Polysaccharide-Conjugate Vaccines: Length Stabilization of Opsono-phagocytic Conformational Polysaccharide Epitopes. Infect Immun, 1998, 66(6): 2441-2446

[22] LaferrièreCA, SoodRK, De MuysJ-M, et al.. The synthesis of Streptococcus pneumoniae polysaccharide-tetanus toxoid conjugates and the effect of chain length on immunogenicity. Vaccine, 1997, 15(2): 179-186

[23] KaplonekP, KhanN, ReppeK, et al.. Improving vaccines against Streptococcus pneumoniae using synthetic glycans. Proc Natl Acad Sci, 2018, 115(52): 13353-13358

[24] SchumannB, ReppeK, KaplonekP, et al.. Development of an Efficacious, Semisynthetic Glycoconjugate Vaccine Candidate against Streptococcus pneumoniae Serotype 1. ACS Cent Sci, 2018, 4(3): 357-361

[25] Javed, MandalPK. Bacterial surface capsular polysaccharides from Streptococcus pneumoniae: A systematic review on structures, syntheses, and glycoconjugate vaccines. Carbohydr Res, 2021, 502: 108277

[26] SchneersonR, BarreraO, SuttonA, et al.. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med, 1980, 152(2): 361-376

[27] FraschCE. Preparation of bacterial polysaccharide—protein conjugates: Analytical and manufacturing challenges. Vaccine, 2009, 27(46): 6468-6470

[28] JinZ, ChuC, RobbinsJB, et al.. Preparation and Characterization of Group A Meningococcal Capsular Polysaccharide Conjugates and Evaluation of Their Immunogenicity in Mice. Infect Immun, 2003, 71(9): 5115-5120

[29] AvciFY, LiX, TsujiM, et al.. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med, 2011, 17(12): 1602-1609

[30] DaganR, PoolmanJ, SiegristCA. Glycoconjugate vaccines and immune interference: A review. Vaccine, 2010, 28(34): 5513-5523

[31] WoodruffMC, KimEH, LuoW, et al.. B Cell Competition for Restricted T Cell Help Suppresses Rare-Epitope Responses. Cell Rep, 2018, 25(2): 321-327

[32] FattomA, ChoYH, ChuC, et al.. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine, 1999, 17(2): 126-133

[33] PorroM, CostantinoP, GiovannoniF, et al.. A molecular model of artificial glycoprotein with predetermined multiple immunodeterminants for gram-positive and gram-negative encapsulated bacteria. Mol Immunol, 1986, 23(4): 385-391

[34] YehSH, GurtmanA, HurleyDC, et al.. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers. Pediatrics, 2010, 126(3): e493-e505

[35] Fitz-PatrickD, YoungMJr, ScottDA, et al.. Arandomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States. Hum Vacc Immunother, 2021, 17(7): 1-8

[36] Caro-AguilarI, IndrawatiL, KaufholdRM, et al.. Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain. Vaccine, 2017, 35(6): 865-872

RIGHTS & PERMISSIONS

Huazhong University of Science and Technology